Nanoparticles loaded with antifungal drug for the treatment of skin infection
Keywords:
amphotericin B, bioavailability, nanotechnology, skin diseaseAbstract
Recent studies have concentrated on different formulations of polymeric nanoparticles. The oral bioavailability of water-insoluble medications has also increased because to advancements made possible by nanotechnology. Evaporation of the solvent and interfacial polymerization are two more methods that can be used in addition to these. Because of its nature as a macrolide pharmaceutical substance, it is especially prone to deterioration when exposed to organic solvents and heat; hence, these processes might not be optimal. On the other hand, coacervation is a sort of encapsulation that is less severe and more straightforward. There are two distinct types of nanoparticulate compositions. Although these formulations are more costly, researchers claim that they cause less damage to the kidneys. Many different resources have created delivery strategies that are both less dangerous to the kidneys and less costly. The current work utilized polyelectrolyte complexation technology in order to generate nanoparticle dosage forms with the intention of maximizing the oral bioavailability of amphotericin B (AmB). Oral bioavailability can be increased thanks to these polymers, which are also biocompatible and biodegradable.
Downloads
References
Allugunti V.R (2022). A machine learning model for skin disease classification using
convolution neural network. International Journal of Computing, Programming and Database
Gondal JA, Swartz RP, Rahman A. Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Agents Chemother. 1989 Sep;33(9):1544–1548.
Graybill JR, Craven PC, Taylor RL, Williams DM, Magee WE. Treatment of murine cryptococcosis with liposome-associated amphotericin B. J Infect Dis. 1982 May;145(5):748–752.
Graybill JR, Palou E, Ahrens J. Treatment of murine histoplasmosis with UK 49,858 (fluconazole). Am Rev Respir Dis. 1986 Oct;134(4):768–770
Holmberg K, Meyer RD. Fungal infections in patients with AIDS and AIDS-related complex. Scand J Infect Dis. 1986;18(3):179–192.
Hospenthal DR, Rogers AL, Beneke ES. Effect of attachment of anticandidal antibody to the surfaces of liposomes encapsulating amphotericin B in the treatment of murine candidiasis. Antimicrob Agents Chemother. 1989 Jan;33(1):16–18.
hrens J, Graybill JR, Craven PC, Taylor RL. Treatment of experimental murine candidiasis with liposome-associated amphotericin B. Sabouraudia. 1984;22(2):163–166.
Janoff AS, Boni LT, Popescu MC, Minchey SR, Cullis PR, Madden TD, Taraschi T, Gruner SM, Shyamsunder E, Tate MW, et al. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci U S A. 1988 Aug;85(16):6122–6126.
Katz NM, Pierce PF, Anzeck RA, Visner MS, Canter HG, Foegh ML, Pearle DL, Tracy C, Rahman A. Liposomal amphotericin B for treatment of pulmonary aspergillosis in a heart transplant patient. J Heart Transplant. 1990 Jan-Feb;9(1):14–17.
Kirsh R, Goldstein R, Tarloff J, Parris D, Hook J, Hanna N, Bugelski P, Poste G. An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. J Infect Dis. 1988 Nov;158(5):1065–1070.
Kobayashi GS, Travis SJ, Medoff G. Comparison of fluconazole and amphotericin B in treating histoplasmosis in immunosuppressed mice. Antimicrob Agents Chemother. 1987 Dec;31(12):2005–2006.
Kumar, S. (2022). A quest for sustainium (sustainability Premium): review of sustainable bonds. Academy of Accounting and Financial Studies Journal, Vol. 26, no.2, pp. 1-18
Kusumawati, A. H., Wulan, I. R., & Ridwanuloh, D. (2020). Formulation and physical evaluation sheet mask from red rice (Oryza Nivara) and virgin coconut oil (Cocos Nucifera L). International Journal of Health & Medical Sciences, 3(1), 60-64. https://doi.org/10.31295/ijhms.v3n1.148
Lopez-Berestein G, Bodey GP, Fainstein V, Keating M, Frankel LS, Zeluff B, Gentry L, Mehta K. Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med. 1989 Nov;149(11):2533–2536.
Lopez-Berestein G, Bodey GP, Frankel LS, Mehta K. Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. J Clin Oncol. 1987 Feb;5(2):310–317.
Lopez-Berestein G, Fainstein V, Hopfer R, Mehta K, Sullivan MP, Keating M, Rosenblum MG, Mehta R, Luna M, Hersh EM, et al. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis. 1985 Apr;151(4):704–710.
Lopez-Berestein G, Hopfer RL, Mehta R, Mehta K, Hersh EM, Juliano RL. Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice. J Infect Dis. 1984 Aug;150(2):278–283.
Lopez-Berestein G, Mehta R, Hopfer RL, Mills K, Kasi L, Mehta K, Fainstein V, Luna M, Hersh EM, Juliano R. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis. 1983 May;147(5):939–945.
Management 3(1), 141-147
Mardon DN, Gunn JL, Robinette E., Jr Variation in the lethal response in mice to yeast-like and pseudohyphal forms of Candida albicans. Can J Microbiol. 1975 Nov;21(11):1681–1687.
Patterson TF, Miniter P, Dijkstra J, Szoka FC, Jr, Ryan JL, Andriole VT. Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes. J Infect Dis. 1989 Apr;159(4):717–724.
Sculier JP, Coune A, Meunier F, Brassinne C, Laduron C, Hollaert C, Collette N, Heymans C, Klastersky J. Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. Eur J Cancer Clin Oncol. 1988 Mar;24(3):527–538.
Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Health and treatment of diabetes mellitus. International Journal of Health Sciences, 5(1), i-v. https://doi.org/10.53730/ijhs.v5n1.2864
Szoka FC, Jr, Milholland D, Barza M. Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B. Antimicrob Agents Chemother. 1987 Mar;31(3):421–429.
Taylor RL, Williams DM, Craven PC, Graybill JR, Drutz DJ, Magee WE. Amphotericin B in liposomes: novel therapy for histoplasmosis. Am Rev Respir Dis. 1982 May;125(5):610
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
